Xeris Biopharma (XERS) reported $83.13 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 38.3%. EPS of $0.01 for the same period compares to -$0.06 a year ago.
The reported revenue represents a surprise of +3.88% over the Zacks Consensus Estimate of $80.03 million. With the consensus EPS estimate being $0, the company has not delivered EPS surprise.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Xeris Biopharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product Revenue- Gvoke: $20.8 million compared to the $21.94 million average estimate based on four analysts. Product Revenue- Recorlev: $49.77 million versus the four-analyst average estimate of $44.78 million. Revenue- Royalty, contract and other: $0.67 million versus the four-analyst average estimate of $1.85 million. Revenue- Product revenue, net: $82.45 million compared to the $78.19 million average estimate based on four analysts. Product Revenue- Keveyis: $11.89 million versus $11.47 million estimated by four analysts on average.View all Key Company Metrics for Xeris Biopharma here>>>
Shares of Xeris Biopharma have returned +7.6% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Xeris Biopharma Holdings, Inc. (XERS): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).